Production of Synthetic Adjuvant System (SAS)

Inimmune Corporation, Missoula MT

Investigators

Abstract

The company will develop a synthetic adjuvant system (SAS) containing a TLR-4 agonist combined with a saponin-based adjuvant, in which both components synergize to elicit a Th1-biased immune response.